Skip to content
Triangle logo TriangleGet started
← Study library

NCT01548573 · REGISTRY CONDITION SEARCH

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2017-06-14

This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding bortezomib (Velcade®), thalidomide, gemcitabine and carmustine to the transplant regimens to down-regulate the rescue of myeloma cells by the micro-environment and to prevent DNA repair post high-dose alkylating agent therapy. By reducing drug resistance, it is hoped that 3-year event-free survival will be increased significantly when compared to Total Therapy II. Additionally, participants will have the option of providing biospecimens for a sub-study evaluating gene expression profiling at specific timepoints to better understand drug-resistance in myeloma, and to determine whether there are genes or gene products in the resistant population that can be targeted by novel therapies.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Event-Free Survival (EFS)

→

outcome · POSTED

Identification of Drug Resistant Genes

→

outcome · POSTED

Number of Grade 3 Non-hematologic and Grade 4 Hematologic Serious Adverse Events Associated With the Addition of Bortezomib, Thalidomide, and Dexamethasone Into Autologous Transplant Regimens.

→

outcome · POSTED

Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Participants must have had a diagnosis of symptomatic MM, MM + amyloidosis, or POEMS (osteosclerotic myeloma: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) requiring treatment. Participants with a previous history of smoldering myeloma will be eligible if there is evidence of progressive disease requiring chemotherapy. Note that study participants do not need to have active disease at the time of study entry, as participants may have received up to 12 months of prior chemotherapy, which might have induced a response. 2. Protein criteria must be present (quantifiable M-component of IgG, IgA, IgD, or IgE and/or urinary kappa or lambda light chain, Bence-Jones protein, or Free Kappa Light Chain or Free Lambda Light Chain) in order to evaluate response. Non-secretory participants are eligible provided the participant has \> 20% plasmacytosis OR multiple (\>3) focal plasmacytomas or focal lesions on MRI. 3. Participants must have received no more than 12 months of prior chemotherapy for this disease. Participants may have received prior radiotherapy provided approval has been obtained from the PI. 4. Participants must not have had a prior transplant. 5. Participants must be 18-80 years of age at the time of study entry. 6. Ejection fraction by ECHO or MUGA of ≥ 40% performed. 7. Participants must have adequate pulmonary function studies, \> 50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity (DLCO) \> 50% of predicted (adjusted for hemoglobin). If the participant is unable to complete pulmonary function tests due to disease related pain or condition, a participant may still be enrolled provided that the PI or enrolling investigator documents that the participant is a transplant candidate. 8. Participants must have a creatinine \< 3 mg/dl and a calculated creatinine clearance \>30mL/min. The Cockroft-Gault equation may be used to obtain calculated creatinine clearance. 9. Participants must have a performance status of 0-2 based on ECOG criteria. Participants with a poor performance status (3-4)based solely on bone pain will be eligible, provided there is documentation to verify this. 10. Participants must sign the most current IRB-approved study ICF (Informed Consent Form). Exclusion Criteria: 1. Prior autologous or allogeneic transplant. 2. Platelet count \< 30 x 109/L, unless myeloma-related. If MM-related, the enrolling investigator must document this. 3. \> grade 3 neuropathy. 4. Known hypersensitivity to bortezomib, boron, or mannitol. 5. Uncontrolled diabetes. 6. Recent (\< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias. 7. Participants must not have light chain deposition disease-related renal failure or creatinine \>3 mg/dl. 8. Participants must not have a concurrent malignancy unless it can be adequately treated by surgical, non-chemotherapeutic intervention. Participants may have a history of prior malignancy, provided that he/she has not had any treatment within 365 days of study entry AND that life expectancy exceeds 5 years at the time of study entry. 9. Participants must not have life-threatening co-morbidities. 10. Women of child-bearing potential must have a documented negative pregnancy test documented within one week of study entry. Women and men of reproductive potential may not participate unless they have agreed, by signing the study ICF, to use effective contraceptive method(s) as outlined in that form.
healthy Volunteers
false
maximum Age
80 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required. After collection, participants will receive dexamethasone x 4 days every 14 days. Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan. Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days. Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles.
    intervention Names
    1. Drug: Dexamethasone
    2. Procedure: Tandem autologous stem cell transplant
    3. Drug: Cisplatin
    4. Drug: Doxorubicin
    5. Drug: Cyclophosphamide
    6. Drug: Etoposide
    7. Drug: Bortezomib
    8. Drug: Thalidomide
    9. Drug: Melphalan
    label
    Tandem autologous stem cell transplant
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given PO
    name
    Dexamethasone
    other Names
    1. Aeroseb-Dex
    2. Decaderm
    3. Decadron
    4. DM
    5. DXM
    type
    DRUG
  2. arm Group Labels
    1. Tandem autologous stem cell transplant
    name
    Tandem autologous stem cell transplant
    type
    PROCEDURE
  3. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given IV
    name
    Cisplatin
    other Names
    1. CACP
    2. CDDP
    3. CPDD
    4. DDP
    type
    DRUG
  4. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given IV
    name
    Doxorubicin
    other Names
    1. ADM
    2. ADR
    3. Adria
    4. Adriamycin PFS
    5. Adriamycin RDF
    type
    DRUG
  5. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given IV or PO
    name
    Cyclophosphamide
    other Names
    1. CPM
    2. CTX
    3. Cytoxan
    4. Endoxan
    5. Endoxana
    type
    DRUG
  6. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given IV
    name
    Etoposide
    other Names
    1. EPEG
    2. VP-16
    3. VP-16-213
    4. Vepesid
    type
    DRUG
  7. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given IV
    name
    Bortezomib
    other Names
    1. LDP 341
    2. MLN341
    3. VELCADE
    type
    DRUG
  8. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given PO
    name
    Thalidomide
    other Names
    1. Kevadon
    2. Synovir
    3. THAL
    4. Thalomid
    type
    DRUG
  9. arm Group Labels
    1. Tandem autologous stem cell transplant
    description
    Given IV
    name
    Melphalan
    other Names
    1. Alkeran
    2. CB-3025
    3. L-PAM
    4. L-phenylalanine mustard
    5. L-Sarcolysin
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
19
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    To determine whether, in comparison to Total Therapy II, the median Event-Free Survival (EFS) can be increased from 4.8 years to 7.2 years, which represents an increase in median EFS of approximately 50%, based on an intent-to-treat analysis.
    measure
    Event-Free Survival (EFS)
    time Frame
    8 years
  2. description
    To determine whether repeated bone marrow samples analyzed for gene expression profiling (GEP) can identify genes related to drug resistance in myeloma. The drug resistant genes or the gene products might then be targeted specifically to eradicate myeloma cells surviving tandem transplantation.
    measure
    Identification of Drug Resistant Genes
    time Frame
    5 years
secondary Outcomes
  1. description
    To determine whether bortezomib, thalidomide and dexamethasone with transplant 1 and velcade/gemcitabine with transplant 2 can be safely incorporated into well-tested pre-transplant regimens of high-dose melphalan and carmustine/melphalan in doses equivalent to the BEAM(BCNU, etoposide, arabinoside, melphalan)regimen. Treatment-related toxicities will be compared to those reported in the literature using similar intensive approaches.
    measure
    Number of Grade 3 Non-hematologic and Grade 4 Hematologic Serious Adverse Events Associated With the Addition of Bortezomib, Thalidomide, and Dexamethasone Into Autologous Transplant Regimens.
    time Frame
    2 years
  2. description
    To determine the median overall survival based on an intent-to-treat analysis, which should exceed 10 years, based on the projected 10-year survival of Total Therapy III, keeping in mind that participants are included in this protocol with up to 12 months of prior therapy.
    measure
    Overall Survival
    time Frame
    10 years
Full study description
brief Summary
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding bortezomib (Velcade®), thalidomide, gemcitabine and carmustine to the transplant regimens to down-regulate the rescue of myeloma cells by the micro-environment and to prevent DNA repair post high-dose alkylating agent therapy. By reducing drug resistance, it is hoped that 3-year event-free survival will be increased significantly when compared to Total Therapy II. Additionally, participants will have the option of providing biospecimens for a sub-study evaluating gene expression profiling at specific timepoints to better understand drug-resistance in myeloma, and to determine whether there are genes or gene products in the resistant population that can be targeted by novel therapies.
detailed Description
This study is targeted towards patients who have been diagnosed with Multiple Myeloma, POEMS(Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes), or myeloma plus amyloidosis and have had no more than 12 months of prior treatment. Furthermore, participants cannot have had a prior autologous or allogeneic transplant. The study schema consists of one round of induction chemotherapy, two transplants, one round of consolidation chemotherapy, and two years of maintenance treatment. This study design differs from its historical predecessors in the following manner: * In contrast to Total Therapy II and III, which only allow enrollment of patients with one cycle or one month of treatment prior to enrollment, the proposed study allows enrollment of participants with up to 12 months of prior treatment. * Induction therapy has been reduced to a single cycle. * Bortezomib and thalidomide have been added to the transplant regimen. * Carmustine is added to the second transplant. * Gemcitabine is added to the second transplant regimen. * Consolidation treatment has been reduced to a single cycle. * The first year of maintenance consists of 12 28-day cycles of bortezomib,dexamethasone, and either thalidomide, lenalidomide, or cyclophoshamide. The second year of maintenance therapy consists of lenalidomide and dexamethasone. * The novel agents thalidomide and bortezomib are not introduced upfront, but only with transplantation, consolidation, and maintenance.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-35b911bb266b8f99a93c
      requested nct id
      NCT01548573
      primary nct id
      NCT01548573
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      ed082b3bf5c4b2a3ca18ed56236c0c2faf34c4d956e03ad9167ca493c600bcdc
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-35b911bb266b8f99a93c
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01548573
      occurrences
      1. context exact
        NCT01548573
        end
        11
        exact text
        NCT01548573
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/650/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      2c33af5fd0de196e66a6aca787fe8f2e54c24248d1e688a34509238b7cff8acf

    Preserved source evidence · Not medical advice